1
|
Han Z, Jia Q, Zhang J, Chen M, Wang L, Tong K, He W, Zhang Y, Zhu W, Qin J, Wang T, Liu T, Ma Y, Chen Y, Zha S, Zhang C. Deubiquitylase YOD1 regulates CDK1 stability and drives triple-negative breast cancer tumorigenesis. J Exp Clin Cancer Res 2023; 42:228. [PMID: 37667382 PMCID: PMC10478497 DOI: 10.1186/s13046-023-02781-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2023] [Accepted: 07/25/2023] [Indexed: 09/06/2023] Open
Abstract
BACKGROUND Accumulating evidence has demonstrated that aberrant expression of deubiquitinating enzymes is associated with the initiation and progression of Triple-negative breast cancer (TNBC). The publicly available TCGA database of breast cancer data was used to analyze the OTUD deubiquitinating family members that were correlated with survival of breast cancer and ovarian tumor domain-containing 2 (OTUD-2), or YOD1 was identified. The aim of present study was to assess YOD1 expression and function in human TNBC and then explored the underlying molecular events. METHODS We detected the expression of YOD1 in 32 TNBC and 44 NTNBC samples by qRT-PCR, Western blot and immunohistochemistry. Manipulation of YOD1 expression was assessed in vitro and in vivo for TNBC cell proliferation, migration, invasion, cell-cycle and drug resistance, using colony formation assay, transwell assay, CCK8 assay, TUNEL assay, flow cytometric analysis and xenograft tumor assay. Next, proteomic analysis, Western blot, proximity ligation assay, Immunoprecipitation, and Immunofluorescence were conducted to assess downstream targets. RESULTS It was found that YOD1 was significantly upregulated in TNBC tissues compared with non-triple-negative breast cancer (NTNBC), which was positively correlated with poor survival in TNBC patients. Knockdown of YOD1 effectively inhibited TNBC cell migration, proliferation, cell cycle and resistance to cisplatin and paclitaxel. Mechanistically, YOD1 promoted TNBC progression in a manner dependent on its catalytic activity through binding with CDK1, leading to de-polyubiquitylation of CDK1 and upregulation of CDK1 expression. In addition, YOD1 overexpression was found to be correlated with CDK1 overexpression in human TNBC specimens. Finally, in vivo study demonstrated that YOD1 knockdown or YOD1 inhibitor could inhibit CDK1 expression and suppress the growth and metastasis of TNBC tumors. CONCLUSION Our study highlights that YOD1 functions as an oncogene in TNBC via binding to CDK1 and mediated its stability and oncogenic activity. Interfering with YOD1 expression or YOD1 inhibitor could suppress TNBC cells in vitro and in vivo, suggesting that YOD1 may prove to be a promising therapeutic target for TNBC.
Collapse
Affiliation(s)
- Zhitao Han
- School of Chinese Medicine, School of Integrated Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China
- Nanjing Hospital of Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China
| | - Qi Jia
- Department of Orthopaedic Oncology, Shanghai Changzheng Hospital, The Second Affiliated Hospital of Naval Medical University, Shanghai, China
| | - Jing Zhang
- Department of Orthopaedic Oncology, Shanghai Changzheng Hospital, The Second Affiliated Hospital of Naval Medical University, Shanghai, China
| | - Miaomiao Chen
- Key Laboratory of Digital Technology in Medical Diagnostics of Zhejiang Province, Hangzhou, Zhejiang, China
| | - Lining Wang
- School of Chinese Medicine, School of Integrated Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China
| | - Kai Tong
- Nanjing Hospital of Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China
| | - Weiwei He
- Nanjing Hospital of Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China
| | - Yajie Zhang
- Central Laboratory, Nanjing Hospital of Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China
- Department of Biobank, Nanjing Hospital of Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China
| | - Weina Zhu
- Central Laboratory, Nanjing Hospital of Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China
- Department of Biobank, Nanjing Hospital of Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China
| | - Ju Qin
- Central Laboratory, Nanjing Hospital of Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China
| | - Tao Wang
- Department of Orthopedics, Second Hospital of Anhui Medical University, Hefei, Anhui, China
| | - Tielong Liu
- Department of Orthopaedic Oncology, Shanghai Changzheng Hospital, The Second Affiliated Hospital of Naval Medical University, Shanghai, China
| | - Yong Ma
- School of Chinese Medicine, School of Integrated Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
| | - Yuanming Chen
- Department of Orthopedics, Second Affiliated Hospital of Guangxi Medical University, 166 East Daxue Road, Nanning, 530000, Guangxi, China.
| | - Siluo Zha
- Department of General Surgery, Shanghai Changzheng Hospital, The Second Affiliated Hospital of Naval Medical University, Shanghai, 200003, China.
| | - Chunlei Zhang
- Nanjing Hospital of Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
- Department of Orthopedics, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, 157 Daming Road, Nanjing, 210023, China.
| |
Collapse
|
2
|
Zha S, Rogstadkjernet M, Scheirlynck ES, Aalen JM, Larsen CK, Cosijns B, Droogmans S, Smiseth OA, Samset E, Edvardsen T, Brekke PH. A deep learning approach for automatic echocardiographic right ventricular strain measurements using a limited dataset. Eur Heart J 2022. [PMCID: PMC9619498 DOI: 10.1093/eurheartj/ehac544.062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Background Speckle tracking echocardiography provides quantification of myocardial deformation and is useful in the assessment of myocardial function. Right ventricular (RV) strain has been suggested as a sensitive tool for diagnosing cardiomyopathies and assessing long term patient outcomes for patients with pulmonary hypertension, severe tricuspid regurgitation and COVID-19 infection. Recent advances in deep learning (DL) have made promising advances in automating the labour-intensive delineation of regions of interest (ROIs). However, compared to echocardiograms with left ventricular (LV) strain, RV strain data is scarce, making DL models difficult to train. Purpose To investigate whether annotated LV strain data could be beneficial in training a DL model for automatic RV strain when using a limited RV dataset. Methods The dataset consisted of anonymized still frames from 141 echocardiograms of the RV in the RV-focused 4 chamber view with corresponding cardiologist-defined ROI. Exams included healthy subjects and patients with heart failure, valvular disease, and conduction abnormalities. ROIs and still images were extracted at the mid-systole, and then quality assessed by an experienced cardiologist as high, medium, or low. The dataset was randomly split into 68%/17%/15% sets for training, validation, and testing. A convolutional neural network for image segmentation (U-Net) with a residual neural network (ResNet50) encoder was used, with a combination of binary cross entropy and Dice loss functions. Augmentation, predefined ImageNet weights and pre-training were also employed. For pre-training, 715 still images in the apical 4 chamber view with LV defined ROIs were used, both in their original and horizontally flipped view. Predicted ROIs were reintroduced into commercially available echocardiogram analysis software to automatically calculate longitudinal strain (LS) values. Results The model pre-trained with the flipped LV images achieved the highest performance with a mean absolute difference of 1.26 percentage points (95% confidence interval (CI): 0.62–1.89 percentage points) between manually measured and DL-assisted LS. Median absolute LS difference was 0.85 (95% CI: 0.28–1.57) percentage points. A Bland-Altman plot revealed two outliers and no obvious trends. In comparison, the mean and median absolute LS differences for the model without pre-training were 1.87 (95% CI: 0.73–3.00) and 1.09 (95% CI: 0.56–1.63) percentage points, respectively. Conclusions The current study demonstrates that DL-assisted, automated RV strain measurement is feasible even with a small dataset, and that performance can be increased by using images annotated for LV strain. While the majority of the predicted RV strain results were within the typical range of intra- and interobserver variability, a few outliers were observed. These outliers could possibly be avoided with the use of larger datasets. Funding Acknowledgement Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Research council of Norway
Collapse
Affiliation(s)
- S Zha
- University of Oslo , Oslo , Norway
| | | | - E S Scheirlynck
- University Hospital (UZ) Brussels, Internal medicine , Brussels , Belgium
| | - J M Aalen
- Oslo University Hospital Rikshospitalet, Cardiology , Oslo , Norway
| | - C K Larsen
- Oslo University Hospital Rikshospitalet, Cardiology , Oslo , Norway
| | - B Cosijns
- University Hospital (UZ) Brussels, Cardiology , Brussels , Belgium
| | - S Droogmans
- University Hospital (UZ) Brussels, Cardiology , Brussels , Belgium
| | - O A Smiseth
- Oslo University Hospital Rikshospitalet, Cardiology , Oslo , Norway
| | - E Samset
- University of Oslo, Informatics , Oslo , Norway
| | - T Edvardsen
- Oslo University Hospital Rikshospitalet, Cardiology , Oslo , Norway
| | - P H Brekke
- Oslo University Hospital Rikshospitalet, Cardiology , Oslo , Norway
| |
Collapse
|
3
|
Lu H, Zha S, Zhang W, Wang Q, Jiang D, Xu X, Zheng X, Qiu M, Shan C. A systematic review and meta-analysis of nab-paclitaxel mono-chemotherapy for metastatic breast cancer. BMC Cancer 2021; 21:830. [PMID: 34275458 PMCID: PMC8286600 DOI: 10.1186/s12885-021-08441-z] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2020] [Accepted: 06/04/2021] [Indexed: 01/15/2023] Open
Abstract
Background Although various clinical trials and real-life studies have tried to explore the value of nab-paclitaxel mono-chemotherapy for metastatic breast cancer (MBC), the safety and efficacy of nab-paclitaxel remain unclear which need to be systematically evaluated. Methods Electronic searches for prospective clinical trials evaluating nab-paclitaxel monotherapy for MBC were performed. Requisite data were extracted, integrated and analysed from the included studies according to the different study designs using systematic review and meta-analysis. Meta-regression and subgroup analysis were further performed to explore the potential risk factors affecting each individual outcome of interest following nab-paclitaxel monotherapy. Results Twenty-two studies with 3287 MBC patients were included. A total of 1685 MBC patients received nab-paclitaxel as first-line therapy, 640 patients as further-line therapy, and 962 patients as mixed-line therapy. A total of 1966 MBC patients (60.40%) received nab-paclitaxel weekly, 1190 patients (36.56%) received nab-paclitaxel triweekly and 99 patients (3.04%) received nab-paclitaxel biweekly. The overall incidence rates of all-grade neutropenia, leukopenia, peripheral sensory neuropathy, and fatigue were 52% (95% CI, 38–66%, I2 = 98.97%), 58% (95% CI, 43–73%, I2 = 97.72%), 58% (95% CI, 48–68%, I2 = 97.17%), and 49% (95% CI, 41–56%, I2 = 94.39%), respectively. The overall response rate (ORR) was 40% (95% CI, 35–45%, I2 = 98.97%), and the clinical benefit rate (CBR) was 66% (95% CI, 59–73%, I2 = 98.97%) following nab-paclitaxel monotherapy. The median progression-free survival (PFS) was 7.64 months (95% CI, 6.89–8.40 months, I2 = 92.3%), and the median overall survival (OS) was 24.51 months (95% CI, 21.25–27.78 months, I2 = 92.7%). Treatment line, human epidermal growth factor receptor-2(Her-2)-negative status and dosage were found to be sources of heterogeneity among the included studies. According to the meta-regression and subgroup analysis, grade 3/4 neutropenia occurred less frequently in Her-2-negative patients than in the entire population (P = 0.046). Patients who received first-line nab-paclitaxel monotherapy showed a higher ORR (P = 0.006) and longer PFS (P = 0.045). Efficacy outcomes were not affected by the administration schedule. However, within the same schedule, patients appeared to have a superior ORR (P = 0.044) and longer PFS (P = 0.03) with an increasing dosage of nab-paclitaxel administered. Conclusions The benefits brought by nab-paclitaxel mono-chemotherapy in the treatment of MBC are considerable while the harm is generally manageable. Further study and validation are needed to figure out the roles which the dosage, schedule and other factors play actually in nab-paclitaxel chemotherapy. Supplementary Information The online version contains supplementary material available at 10.1186/s12885-021-08441-z.
Collapse
Affiliation(s)
- Haili Lu
- Third Division of Department of General Surgery of Changzheng Hospital affiliated with Naval Military Medical University, Fengyang Road, Shanghai, 200003, China
| | - Siluo Zha
- Third Division of Department of General Surgery of Changzheng Hospital affiliated with Naval Military Medical University, Fengyang Road, Shanghai, 200003, China
| | - Wei Zhang
- Third Division of Department of General Surgery of Changzheng Hospital affiliated with Naval Military Medical University, Fengyang Road, Shanghai, 200003, China
| | - Qiang Wang
- Third Division of Department of General Surgery of Changzheng Hospital affiliated with Naval Military Medical University, Fengyang Road, Shanghai, 200003, China
| | - Daozhen Jiang
- Third Division of Department of General Surgery of Changzheng Hospital affiliated with Naval Military Medical University, Fengyang Road, Shanghai, 200003, China
| | - Xinyun Xu
- Third Division of Department of General Surgery of Changzheng Hospital affiliated with Naval Military Medical University, Fengyang Road, Shanghai, 200003, China
| | - Xiangmin Zheng
- Third Division of Department of General Surgery of Changzheng Hospital affiliated with Naval Military Medical University, Fengyang Road, Shanghai, 200003, China
| | - Ming Qiu
- Third Division of Department of General Surgery of Changzheng Hospital affiliated with Naval Military Medical University, Fengyang Road, Shanghai, 200003, China
| | - Chengxiang Shan
- Third Division of Department of General Surgery of Changzheng Hospital affiliated with Naval Military Medical University, Fengyang Road, Shanghai, 200003, China.
| |
Collapse
|
4
|
Li W, Liu B, Shan C, Liu Z, Wang Q, Rao W, Zha S, Zhang W, Qiu M. Application of carbon nanoparticles in localization of parathyroid glands during total parathyroidectomy for secondary hyperparathyroidism. Am J Surg 2020; 220:1586-1591. [PMID: 32423601 DOI: 10.1016/j.amjsurg.2020.04.034] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2020] [Revised: 04/22/2020] [Accepted: 04/24/2020] [Indexed: 10/24/2022]
Abstract
BACKGROUND Intraoperative imaging is used to address the challenges of parathyroidectomy, but no standard modality has been established. This study aimed to assess whether carbon nanoparticle injection is useful in localizing parathyroid glands (PGs) during parathyroidectomy. METHODS Patients who underwent total parathyroidectomy (TPTX) between September 2015 and November 2018 were included. The operative duration and intact parathyroid hormones (iPTH) were analyzed. RESULTS A total of 61 patients were included; of these, 32 with carbon nanoparticle injection (TPTX + CN group) and 29 without (TPTX group). The operative duration in the TPTX + CN group was significantly shorter (90.6 ± 21.2 vs 101.4 ± 19.4 min, P = 0.042), which is more apparent in those with normal sized PGs. For those with four enlarged PGs, iPTH levels on 1 day and 1 year postoperatively were significantly lower in the TPTX + CN group (P = 0.032 and P = 0.036, respectively). CONCLUSION Carbon nanoparticles are useful in the identification normal sized PGs and complete resection of enlarged PGs.
Collapse
Affiliation(s)
- Wei Li
- Department of General Surgery, Changzheng Hospital, Naval medical university, Shanghai, 200003, China
| | - Bingyang Liu
- Department of General Surgery, Changzheng Hospital, Naval medical university, Shanghai, 200003, China
| | - Chengxiang Shan
- Department of General Surgery, Changzheng Hospital, Naval medical university, Shanghai, 200003, China
| | - Zhiyong Liu
- Department of Laboratory Diagnostics, Changhai Hospital, Naval medical university, Shanghai, 200433, China
| | - Qiang Wang
- Department of General Surgery, Changzheng Hospital, Naval medical university, Shanghai, 200003, China
| | - Wensheng Rao
- Department of General Surgery, Changzheng Hospital, Naval medical university, Shanghai, 200003, China
| | - Siluo Zha
- Department of General Surgery, Changzheng Hospital, Naval medical university, Shanghai, 200003, China
| | - Wei Zhang
- Department of General Surgery, Changzheng Hospital, Naval medical university, Shanghai, 200003, China.
| | - Ming Qiu
- Department of General Surgery, Changzheng Hospital, Naval medical university, Shanghai, 200003, China.
| |
Collapse
|
5
|
Zha S, Gage WR, Sauvageot J, Saria EA, Putzi MJ, Ewing CM, Faith DA, Nelson WG, De Marzo AM, Isaacs WB. Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res 2001; 61:8617-23. [PMID: 11751373] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
Abstract
Cyclooxygenase-2 (COX-2) is the inducible isoform of the rate-limiting enzymes that convert arachidonic acid to proinflammatory prostaglandins as well as a primary target for nonsteroidal anti-inflammatory drugs. Accumulating evidence suggests that up-regulation of COX-2 is associated with carcinogenesis in multiple organ systems including the large bowel, lung, breast, and prostate. In this report, we examine the expression of COX-2 protein and mRNA in prostate tissue containing various lesions and in prostate cancer cell lines. In the cell lines, LNCaP, DU145, PC-3, and TSU, COX-2 protein expression was undetectable under basal conditions but could be induced transiently by phorbol ester treatment in PC-3 and TSU cells, but not in DU145 and LNCaP cells. Immunohistochemical analysis of 144 human prostate cancer cases suggested that, in contrast to several previous reports, there was no consistent overexpression of COX-2 in established prostate cancer or high-grade prostatic intraepithelial neoplasia, as compared with adjacent normal prostate tissue. Positive staining was seen only in scattered cells (<1%) in both tumor and normal tissue regions but was much more consistently observed in areas of proliferative inflammatory atrophy, lesions that have been implicated in prostatic carcinogenesis. Staining was also seen at times in macrophages. Western blotting and quantitative RT-PCR analyses confirmed these patterns of expression. These results suggest that if nonsteroidal anti-inflammatory drugs are indeed chemopreventive and/or chemotherapeutic for prostate cancer, their effects are likely to be mediated by modulating COX-2 activity in non-PCa cells (either inflammatory cells or atrophic epithelial cells) or by affecting a COX-2-independent pathway.
Collapse
Affiliation(s)
- S Zha
- Graduate Program of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|